Fresenius Kabi
Clinical trials sponsored by Fresenius Kabi, explained in plain language.
Healthcare company specializing in intravenous drugs, clinical nutrition, and medical devices.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test blood sugar impact of nutritional drink Results expected Dec 2026 (estimated)
-
Fish oil treatment tested for kids with liver damage from IV nutrition
Disease control Recruiting nowThis study is testing the safety of Omegaven, a fish oil-based fat emulsion, in 40 children under 18 who have developed liver problems (cholestasis) from long-term IV nutrition. The main goal is to see how many children develop essential fatty acid deficiency during at least 8 we…
Sponsor: Fresenius Kabi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study checks if IV fat emulsion prevents nutrient shortages in Long-Term patients
Disease control Recruiting nowThis study looks at how safe SMOFlipid is for children and adults who need IV nutrition for 8 weeks or more. It checks if the treatment causes a lack of essential fats or liver problems. About 100 participants will be followed to see how their bodies respond.
Phase 4 • Sponsor: Fresenius Kabi • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC